WASHINGTON, March 7 (Reuters) - Human Genome Sciences Inc’s (HGSI.O) lupus drug is poised to win U.S. clearance this week, offering patients the first approved treatment option in a half-century and setting the company up for blockbuster sales.
WASHINGTON, March 7 (Reuters) - Human Genome Sciences Inc’s (HGSI.O) lupus drug is poised to win U.S. clearance this week, offering patients the first approved treatment option in a half-century and setting the company up for blockbuster sales.
